Regulatory FDA kicks off review of Roche’s Gazyva for wider lupus use PharmaphorumRoche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.RegulatoryImmunology & InflammationRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyNext: Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
